Eaton Vance Ltd Duration Income Fund
Change company Symbol lookup
Select an option...
XEVVX Eaton Vance Ltd Duration Income Fund
JNJ Johnson & Johnson
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
Go

Company profile

Eaton Vance Limited Duration Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation to the extent it is consistent with its primary objective. The Fund may invest in Eaton Vance Cash Reserves Fund, LLC (Cash Reserves Fund). The Fund invests in various sectors, including aerospace and defense, air transport, automotive, beverage and tobacco, brokerage/securities dealers/investment houses, building and development, cable and satellite television, chemicals and plastics, electronics/electrical, financial intermediaries, food products, equipment leasing, lodging and casinos, oil and gas, industrial equipment, home furnishings, leisure goods/activities/movies, healthcare, telecommunications, publishing and insurance, among others. The Fund's investment advisor is Eaton Vance Management (EVM).

Closing Price
$13.48
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

Stocks snap 4-day winning streak as coronavirus vaccine, treatment hit snags

4:08 pm ET October 13, 2020 (MarketWatch)
Print

Stocks ended lower Tuesday, snapping a four-day winning streak for major indexes, as investors weighed separate setbacks in trials for a COVID-19 vaccine and a treatment and sifted through earnings for big Wall Street banks. The Dow Jones Industrial Average fell around 157 points, or 0.5%, to end near 28,681, while the S&P 500 gave up around 22 points, or 0.6%, finishing near 3,512. The Nasdaq Composite closed near 11,864, down 97 points, or 0.8%. Shares of Johnson & Johnson (JNJ) fell 2.9% after Stat News reported that the drug maker had paused its COVID-19 vaccine trial over an "unexplained illness." Later Tuesday, Eli Lilly & Co. (LLY) confirmed that a data safety monitoring board had paused enrollment in a clinical study (http://www.marketwatch.com/story/a-study-testing-lillys-antibody-treatment-and-remdesivir-is-paused-2020-10-13) testing its experimental COVID-19 monoclonal antibody treatment in combination with Gilead Sciences Inc.'s (GILD) remdesivir. Eli Lilly shares ended 2.9% lower.

-William Watts; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 13, 2020 16:08 ET (20:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.